Richardson, Paul G. http://orcid.org/0000-0002-7426-8865
Facon, Thierry
Bensinger, William I.
Leleu, Xavier
Campana, Frank
Macé, Sandrine
Chiron, Marielle
van de Velde, Helgi
Mikhael, Joseph
Article History
Received: 26 October 2020
Revised: 4 February 2021
Accepted: 9 February 2021
First Online: 12 March 2021
Conflict of interest
: P.G.R. reports research funding from Bristol-Myers Squibb, Celgene, Oncopeptides, and Takeda; service on advisory committees for Amgen, Celgene, Janssen, Karyopharm, Oncopeptides, Sanofi, and Takeda. T.F. reports membership on a Board of Directors or advisory committee for Amgen, Celgene, Janssen, Sanofi, and Takeda, and Speakers Bureau for Celgene, Janssen, and Takeda. W.I.B. reports research funding from Amgen and Celgene; Speakers Bureau membership for Janssen and Takeda; receiving personal fees from Amgen and Celgene and grants from Karyopharm, Merck, Sanofi, and Seattle Genetics. X.L. received honoraria from Amgen, BMS, Carsgen, Gilead, Insight, Janssen, Karyopharm, Merck, Novartis, Oncopeptides, Roche, Sanofi, and Takeda. S.M., M.C., and H.vdV. are employed by Sanofi. F.C. was formerly employed by Sanofi. J.M. reports research funding from Amgen, Celgene, and Sanofi; consultant to Amgen, Celgene, GSK, Janssen, Karyopharm, Sanofi, and Takeda.